Anti-VEGF Market is predicted to reach USD 33.4 billion at a CAGR of 4.30% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Anti-VEGF Market”.

The Anti-VEGF market is estimated to register a CAGR of 4.30% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Anti-VEGF market— Regeneron Pharmaceuticals, Novartis AG, Roche, Bayer AG, Allergan plc, Pfizer Inc., Bausch Health Companies Inc., AbbVie Inc., Santen Pharmaceutical Co., Ltd., Alcon Inc., and Others.

Anti VEGF Market Highlights

The global Anti-VEGF market is accounted to register a CAGR of 4.30% during the forecast period and is estimated to reach USD 33.4 billion by 2032.

The Anti-VEGF (Vascular Endothelial Growth Factor) market is expanding due to several factors. Firstly, the rising prevalence of diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal vascular disorders fuels demand for anti-VEGF therapies. Additionally, advancements in biotechnology have led to the development of more effective and targeted anti-VEGF drugs. Furthermore, increasing adoption of these therapies in emerging economies, coupled with aging populations globally, contributes to the overall growth of the Anti-VEGF market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of  Anti VEGF Market 

Segment Analysis

The global Anti-VEGF market has been segmented based on Product and Disease.

On the basis of Product, the market is segmented into Eylea, Lucentis, And Beovu. The Eylea segment captured the largest market share in the Anti-VEGF Market in 2023 due to its proven efficacy and safety profile in treating retinal diseases such as age-related macular degeneration and diabetic retinopathy. Its longer dosing intervals compared to other anti-VEGF agents provide convenience for patients and healthcare providers. Moreover, extensive clinical evidence and strong marketing strategies further solidified Eylea's position as a leading product in the market.

Based on Disease, the global Anti-VEGF market has been segmented into Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, And Age-Related Macular Degeneration. The Macular Edema segment secured the largest market share in the Anti-VEGF Market in 2023 due to its high prevalence and significant impact on vision loss. As a common complication of retinal diseases such as diabetic retinopathy and age-related macular degeneration, the demand for effective treatments, including anti-VEGF therapies, is substantial. Additionally, advancements in diagnosis and increased awareness among patients and healthcare professionals further drove market growth.

Regional Analysis

The global Anti-VEGF market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Anti-VEGF market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Anti-VEGF market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Anti-VEGF market comprises the Middle East, Africa, and Latin America.

North America dominated the Anti-VEGF Market in 2023 primarily due to several factors. These include a high prevalence of retinal diseases, advanced healthcare infrastructure facilitating widespread access to treatment, and robust reimbursement policies supporting expensive therapies. Additionally, extensive research and development activities, coupled with early adoption of innovative treatments, contributed to North America's leading position in the Anti-VEGF Market.

Europe secured the second-largest market share in the Anti-VEGF Market in 2023 due to factors such as a significant patient population suffering from retinal diseases, advanced healthcare systems, and well-established regulatory frameworks facilitating the approval and adoption of anti-VEGF therapies. Moreover, increasing awareness among healthcare professionals and patients about the benefits of these treatments further fueled market growth in Europe.

Asia Pacific is experiencing the highest compound annual growth rate (CAGR) in the Anti-VEGF Market due to several factors. These include a rapidly increasing geriatric population, rising prevalence of retinal diseases, improving healthcare infrastructure, and expanding access to advanced therapies. Additionally, increasing healthcare expenditure, growing awareness about eye health, and rising investments in research and development contribute to the significant growth potential in the Asia Pacific region.

Furthermore, the rest of the world's Anti-VEGF market is divided into the Middle East, Africa, and Latin America. The rest of the world is experiencing growth in the Anti-VEGF market due to factors such as improving healthcare infrastructure, rising awareness about retinal diseases, and increasing availability of advanced treatment options. Additionally, expanding healthcare expenditure and growing partnerships with global pharmaceutical companies contribute to market expansion in these regions.

Key Findings of the Study

• The global Anti-VEGF market is expected to reach USD 33.4 billion by 2032, at a CAGR of 4.30% during the forecast period.


• The Asia Pacific region is experiencing rapid growth in the Anti-VEGF market due to factors such as a large population, increasing prevalence of retinal diseases, expanding healthcare infrastructure, rising healthcare expenditure, and growing awareness.


• Based on Product, the Eylea segment was attributed to holding the largest market in 2023.


• Regeneron Pharmaceuticals, Novartis AG, Roche, Bayer AG, Allergan plc, Pfizer Inc., Bausch Health Companies Inc., AbbVie Inc., Santen Pharmaceutical Co., Ltd., and Alcon Inc. are the key market players.